Muscle-Tropic AAV Capsid Variants: Advancing Targeted Gene Delivery for Neuromuscular Disease Research

Adeno-associated virus, or AAV, has become one of the most important delivery platforms for in vivo gene therapy. In muscle-related diseases, however, naturally occurring AAV serotypes often face important limitations. Many programs require systemic administration to reach widespread skeletal and cardiac muscle, which can lead to high vector doses, broad biodistribution, liver exposure, immune responses, and manufacturing challenges. These limitations have driven strong interest in engineered muscle-tropic AAV capsid variants.

AAV capsid variants are modified forms of the viral protein shell that surrounds the vector genome. Because the capsid controls receptor binding, tissue tropism, cellular uptake, biodistribution, immune recognition, and manufacturability, engineering the capsid can significantly change how an AAV vector behaves in vivo. For muscle-directed applications, the goal is to improve delivery to skeletal muscle, diaphragm, and cardiac muscle while reducing off-target transduction, especially in the liver.

Why Muscle-Directed AAV Delivery Matters

Muscle is a major therapeutic target for many genetic and acquired diseases. It is highly vascularized, widely distributed throughout the body, and relevant to disorders such as Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myotonic dystrophy, Pompe disease, metabolic myopathies, and other neuromuscular conditions. Muscle can also serve as a depot for producing secreted therapeutic proteins.

For systemic muscle diseases, efficient delivery is particularly challenging because the vector must reach large tissue mass across the body. Conventional AAV capsids may require high doses to achieve sufficient muscle transduction, which can increase safety risks and production burden. Engineered muscle-tropic capsids are intended to improve the therapeutic index by increasing target-tissue delivery and reducing unnecessary exposure elsewhere.

How AAV Capsid Variants Improve Muscle Targeting

Muscle-tropic AAV capsids can be generated through several approaches, including rational design, directed evolution, peptide insertion, structure-guided engineering, and high-throughput in vivo screening. Some strategies introduce receptor-binding motifs that improve interaction with muscle-associated receptors, while others select capsids that show enhanced muscle enrichment after systemic delivery.

Potential advantages of muscle-tropic AAV capsid variants include:

• Improved skeletal muscle transduction after systemic or local administration.
• Enhanced delivery to cardiac muscle or diaphragm in selected models.
• Lower effective vector dose for a given level of transgene expression.
• Reduced liver transduction or liver-detargeting compared with some conventional capsids.
• Improved suitability for neuromuscular disease research and therapeutic development.
• Better alignment between capsid design, tissue targeting, and manufacturability.

Recent studies have reported engineered myotropic AAVs such as AAVMYO, MyoAAV-1A, MyoAAV-2A, and other muscle-directed variants with improved muscle delivery compared with some naturally occurring AAV serotypes in preclinical models. A 2024 study also described a rationally designed AAV capsid targeting integrin αVβ6, a skeletal muscle-associated receptor, with the goal of improving skeletal muscle targeting while reducing liver tropism.

Applications in Neuromuscular Disease Research

Engineered muscle-tropic AAV capsids are especially relevant for diseases requiring widespread muscle correction. In Duchenne muscular dystrophy, for example, the full-length dystrophin gene is too large for a single AAV vector, so researchers have explored micro-dystrophin, dual-vector, or multi-vector strategies. More efficient muscle-tropic capsids may help improve delivery efficiency and reduce the total vector dose required for these approaches.

Muscle-tropic capsids are also being studied for metabolic and enzymatic diseases affecting skeletal or cardiac muscle. Improved muscle transduction may support stronger expression of therapeutic proteins, better functional correction in disease models, and more efficient evaluation of candidate therapies. Some recent preclinical work has used engineered myotropic capsids such as MyoAAV4A to improve muscle and heart delivery in dystrophin-related studies.

Beyond therapeutic development, muscle-tropic AAV variants are useful research tools. They can support gene overexpression, knockdown, reporter expression, CRISPR-based studies, disease modeling, and functional analysis in skeletal muscle, diaphragm, heart, and neuromuscular junction-related models.

Scientific and Translational Challenges

Although engineered muscle-tropic AAV capsids offer strong potential, they are not automatically superior in every context. Capsid performance can vary by species, route of administration, tissue type, dose, disease model, and transgene cassette. A capsid that performs well in mice may not show the same tropism or efficiency in non-human primates or humans.

Key challenges include:

• Species translation: Muscle tropism observed in rodent models may not fully predict performance in larger animals or humans.
• Immune recognition: Engineered capsids may still be affected by pre-existing antibodies or capsid-specific immune responses.
• Off-target biodistribution: Even muscle-tropic capsids may transduce liver, heart, dorsal root ganglia, or other tissues depending on dose and route.
• Manufacturing fitness: Capsids with strong biological performance must also be manufacturable at high yield and quality.
• Payload constraints: AAV’s limited packaging capacity remains a major challenge for large muscle genes such as dystrophin.
• Safety and dose: Lower effective dose is a key objective, but dose-response, biodistribution, toxicity, and durability must be carefully evaluated.

These challenges mean that capsid selection should be based on comprehensive data, including tissue tropism, potency, biodistribution, immune profile, vector yield, full capsid ratio, and product quality.

Future Outlook

The future of muscle-directed AAV delivery will likely be shaped by integrated capsid engineering. Instead of optimizing only for transduction, next-generation capsids will need to balance multiple attributes: muscle specificity, cardiac and diaphragm coverage, liver detargeting, immune profile, manufacturability, genome packaging efficiency, and cross-species translation.

High-throughput in vivo screening, barcoded capsid libraries, artificial intelligence, protein language models, and structure-guided design are accelerating discovery of improved AAV capsids. As these tools mature, researchers may be able to design vectors that are better matched to specific muscle diseases, routes of administration, and patient populations.

Conclusion

AAV capsid variants are opening new possibilities for muscle-directed gene delivery. By improving skeletal and cardiac muscle transduction, reducing off-target exposure, and potentially lowering effective vector dose, engineered muscle-tropic capsids may help address some of the most important barriers in neuromuscular gene therapy research.

At the same time, successful translation requires more than improved tropism. Capsid variants must be evaluated for safety, immunogenicity, manufacturability, species relevance, and compatibility with the therapeutic payload. With continued progress in capsid engineering and AAV manufacturing, muscle-tropic AAV variants are expected to play an increasingly important role in the development of next-generation gene therapies for muscle and neuromuscular diseases.